Concepts (347)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Psychomotor Performance | 73 | 2012 | 492 | 7.430 |
Why?
|
| Analgesics, Opioid | 32 | 2014 | 413 | 5.150 |
Why?
|
| Oxycodone | 14 | 2013 | 35 | 4.900 |
Why?
|
| Nitrous Oxide | 28 | 2010 | 107 | 4.350 |
Why?
|
| Affect | 42 | 2011 | 386 | 3.480 |
Why?
|
| Morphine | 19 | 2014 | 130 | 2.710 |
Why?
|
| Narcotics | 12 | 2012 | 69 | 2.500 |
Why?
|
| Anesthetics, Inhalation | 13 | 2018 | 95 | 2.290 |
Why?
|
| Double-Blind Method | 64 | 2018 | 1823 | 2.190 |
Why?
|
| Cross-Over Studies | 45 | 2018 | 399 | 2.180 |
Why?
|
| Substance-Related Disorders | 18 | 2011 | 394 | 1.980 |
Why?
|
| Cognition | 23 | 2011 | 570 | 1.540 |
Why?
|
| Dose-Response Relationship, Drug | 42 | 2019 | 1961 | 1.490 |
Why?
|
| Ethanol | 11 | 2011 | 249 | 1.280 |
Why?
|
| Choice Behavior | 12 | 2008 | 160 | 1.250 |
Why?
|
| Pain | 10 | 2013 | 391 | 1.250 |
Why?
|
| Motivation | 8 | 2013 | 287 | 1.220 |
Why?
|
| Alcohol Drinking | 8 | 2009 | 267 | 1.210 |
Why?
|
| Adult | 104 | 2019 | 25648 | 1.190 |
Why?
|
| Methyl Ethers | 6 | 2008 | 33 | 1.150 |
Why?
|
| Arousal | 13 | 2005 | 170 | 1.080 |
Why?
|
| Opioid-Related Disorders | 9 | 2012 | 161 | 1.070 |
Why?
|
| Smoking | 11 | 2013 | 609 | 1.010 |
Why?
|
| Analgesics | 4 | 2013 | 119 | 0.990 |
Why?
|
| Male | 107 | 2019 | 40965 | 0.960 |
Why?
|
| Hydrocodone | 3 | 2008 | 7 | 0.890 |
Why?
|
| Female | 98 | 2019 | 44532 | 0.870 |
Why?
|
| Carisoprodol | 2 | 2011 | 4 | 0.820 |
Why?
|
| Analgesics, Non-Narcotic | 5 | 2008 | 46 | 0.820 |
Why?
|
| Psychomotor Disorders | 4 | 2008 | 20 | 0.780 |
Why?
|
| Sex Characteristics | 4 | 2010 | 319 | 0.750 |
Why?
|
| Pain Measurement | 10 | 2013 | 321 | 0.750 |
Why?
|
| Humans | 126 | 2019 | 86643 | 0.720 |
Why?
|
| Drug Interactions | 13 | 2012 | 248 | 0.710 |
Why?
|
| Fentanyl | 9 | 1996 | 65 | 0.700 |
Why?
|
| Cold Temperature | 8 | 2004 | 157 | 0.680 |
Why?
|
| Butorphanol | 4 | 2004 | 9 | 0.680 |
Why?
|
| Euphoria | 6 | 2010 | 43 | 0.670 |
Why?
|
| Memory | 7 | 2012 | 225 | 0.600 |
Why?
|
| Behavior | 5 | 1999 | 85 | 0.590 |
Why?
|
| Emotions | 4 | 2011 | 341 | 0.550 |
Why?
|
| Sex Factors | 5 | 2019 | 1054 | 0.530 |
Why?
|
| Muscle Relaxants, Central | 2 | 2011 | 10 | 0.510 |
Why?
|
| Propofol | 6 | 1996 | 89 | 0.500 |
Why?
|
| Hemodynamics | 10 | 2008 | 710 | 0.480 |
Why?
|
| Nausea | 2 | 2013 | 175 | 0.480 |
Why?
|
| Immersion | 4 | 2004 | 21 | 0.480 |
Why?
|
| Hydromorphone | 3 | 2011 | 10 | 0.470 |
Why?
|
| Isoflurane | 4 | 2018 | 64 | 0.470 |
Why?
|
| Healthy Volunteers | 1 | 2014 | 143 | 0.470 |
Why?
|
| Prescription Drug Misuse | 1 | 2013 | 13 | 0.470 |
Why?
|
| Marijuana Smoking | 5 | 1992 | 29 | 0.460 |
Why?
|
| Analysis of Variance | 10 | 2009 | 912 | 0.450 |
Why?
|
| Naltrexone | 1 | 2014 | 135 | 0.440 |
Why?
|
| Injections, Intravenous | 14 | 2001 | 244 | 0.440 |
Why?
|
| Anticonvulsants | 2 | 2011 | 126 | 0.440 |
Why?
|
| Young Adult | 10 | 2014 | 5976 | 0.430 |
Why?
|
| GABA Modulators | 1 | 2012 | 9 | 0.430 |
Why?
|
| Alprazolam | 1 | 2012 | 4 | 0.420 |
Why?
|
| Pupil | 5 | 2014 | 18 | 0.410 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2011 | 28 | 0.410 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2011 | 83 | 0.400 |
Why?
|
| Administration, Inhalation | 10 | 2008 | 188 | 0.390 |
Why?
|
| Surveys and Questionnaires | 14 | 2011 | 2501 | 0.390 |
Why?
|
| Food Deprivation | 4 | 1992 | 24 | 0.380 |
Why?
|
| Analgesia | 3 | 1999 | 57 | 0.370 |
Why?
|
| Receptors, Opioid, mu | 4 | 2014 | 45 | 0.370 |
Why?
|
| Midazolam | 6 | 1996 | 48 | 0.370 |
Why?
|
| Pain Threshold | 4 | 1998 | 58 | 0.360 |
Why?
|
| Acetaminophen | 2 | 2008 | 54 | 0.350 |
Why?
|
| Mental Recall | 5 | 2007 | 159 | 0.350 |
Why?
|
| Reaction Time | 7 | 2012 | 309 | 0.340 |
Why?
|
| Codeine | 3 | 2005 | 12 | 0.340 |
Why?
|
| Anxiety | 1 | 2011 | 287 | 0.340 |
Why?
|
| Dextroamphetamine | 4 | 1992 | 107 | 0.330 |
Why?
|
| Blood Pressure | 7 | 2005 | 1143 | 0.320 |
Why?
|
| Alcoholic Intoxication | 1 | 2008 | 31 | 0.320 |
Why?
|
| Reference Values | 8 | 2009 | 674 | 0.320 |
Why?
|
| Drug Combinations | 4 | 2011 | 224 | 0.310 |
Why?
|
| Caffeine | 3 | 2018 | 81 | 0.310 |
Why?
|
| Naloxone | 2 | 1999 | 59 | 0.300 |
Why?
|
| Anesthetics, Intravenous | 2 | 1997 | 41 | 0.300 |
Why?
|
| Central Nervous System Depressants | 2 | 1997 | 45 | 0.290 |
Why?
|
| Meperidine | 2 | 1999 | 13 | 0.290 |
Why?
|
| Narcotic Antagonists | 3 | 2014 | 154 | 0.290 |
Why?
|
| Fasting | 3 | 1992 | 161 | 0.280 |
Why?
|
| Automobile Driver Examination | 1 | 2006 | 1 | 0.280 |
Why?
|
| Drug Prescriptions | 2 | 2008 | 141 | 0.280 |
Why?
|
| Task Performance and Analysis | 1 | 2006 | 86 | 0.270 |
Why?
|
| Automobile Driving | 1 | 2006 | 31 | 0.270 |
Why?
|
| Impulsive Behavior | 1 | 2009 | 281 | 0.270 |
Why?
|
| Motor Skills | 1 | 2006 | 71 | 0.270 |
Why?
|
| Histamine H2 Antagonists | 1 | 2005 | 15 | 0.270 |
Why?
|
| Tramadol | 1 | 2005 | 14 | 0.270 |
Why?
|
| Carbon Monoxide | 8 | 1992 | 90 | 0.260 |
Why?
|
| Proton Pump Inhibitors | 1 | 2005 | 31 | 0.260 |
Why?
|
| Administration, Oral | 6 | 2011 | 684 | 0.260 |
Why?
|
| Cognition Disorders | 2 | 2005 | 236 | 0.250 |
Why?
|
| Substance Abuse Detection | 3 | 2013 | 12 | 0.250 |
Why?
|
| Valerian | 1 | 2004 | 3 | 0.250 |
Why?
|
| Dextropropoxyphene | 1 | 2004 | 2 | 0.250 |
Why?
|
| Plant Preparations | 1 | 2004 | 19 | 0.250 |
Why?
|
| Lorazepam | 4 | 2005 | 16 | 0.240 |
Why?
|
| Anesthetics | 3 | 1999 | 48 | 0.240 |
Why?
|
| Alcoholism | 2 | 1999 | 172 | 0.240 |
Why?
|
| Gastroesophageal Reflux | 1 | 2005 | 117 | 0.230 |
Why?
|
| Drug and Narcotic Control | 1 | 2003 | 7 | 0.230 |
Why?
|
| Respiration | 7 | 1999 | 262 | 0.230 |
Why?
|
| Marijuana Abuse | 2 | 1994 | 26 | 0.230 |
Why?
|
| Heart Rate | 6 | 2014 | 492 | 0.230 |
Why?
|
| Anesthesia Recovery Period | 3 | 2018 | 56 | 0.230 |
Why?
|
| Tropanes | 1 | 2002 | 2 | 0.230 |
Why?
|
| Nicotine | 5 | 1993 | 194 | 0.220 |
Why?
|
| Preanesthetic Medication | 1 | 2002 | 6 | 0.210 |
Why?
|
| Dental Anxiety | 1 | 2002 | 2 | 0.210 |
Why?
|
| Anesthesia, Dental | 1 | 2002 | 4 | 0.210 |
Why?
|
| Risk Factors | 9 | 2013 | 5417 | 0.210 |
Why?
|
| Time Factors | 11 | 2018 | 5210 | 0.200 |
Why?
|
| Placebos | 4 | 2011 | 218 | 0.200 |
Why?
|
| Anesthesiology | 3 | 1999 | 157 | 0.200 |
Why?
|
| Thiopental | 2 | 1997 | 15 | 0.190 |
Why?
|
| Infusions, Intravenous | 3 | 2014 | 429 | 0.180 |
Why?
|
| Anesthetics, Combined | 1 | 1999 | 4 | 0.180 |
Why?
|
| Prospective Studies | 9 | 2013 | 4213 | 0.180 |
Why?
|
| Azepines | 1 | 2019 | 20 | 0.180 |
Why?
|
| Alfentanil | 1 | 1999 | 2 | 0.170 |
Why?
|
| Research Design | 2 | 2013 | 594 | 0.170 |
Why?
|
| Drug Tolerance | 3 | 1996 | 63 | 0.170 |
Why?
|
| Pentazocine | 1 | 1998 | 2 | 0.170 |
Why?
|
| Citrates | 1 | 2018 | 28 | 0.170 |
Why?
|
| Attention | 5 | 2007 | 388 | 0.160 |
Why?
|
| Anesthesia | 2 | 1999 | 164 | 0.160 |
Why?
|
| Hypnotics and Sedatives | 2 | 1996 | 125 | 0.160 |
Why?
|
| Psychotropic Drugs | 1 | 1999 | 75 | 0.160 |
Why?
|
| Ethers | 1 | 1997 | 14 | 0.160 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2013 | 865 | 0.160 |
Why?
|
| Adjuvants, Anesthesia | 1 | 1997 | 5 | 0.160 |
Why?
|
| Verapamil | 2 | 1997 | 48 | 0.160 |
Why?
|
| Neuropsychological Tests | 4 | 2012 | 502 | 0.160 |
Why?
|
| Individuality | 3 | 2008 | 109 | 0.150 |
Why?
|
| Piperidines | 1 | 1999 | 181 | 0.150 |
Why?
|
| Risk | 2 | 2013 | 674 | 0.150 |
Why?
|
| Nalbuphine | 1 | 1997 | 3 | 0.150 |
Why?
|
| Buprenorphine | 1 | 1997 | 33 | 0.150 |
Why?
|
| Accidents, Occupational | 1 | 1996 | 8 | 0.150 |
Why?
|
| Sulfonamides | 1 | 2019 | 300 | 0.150 |
Why?
|
| Anti-Anxiety Agents | 1 | 1996 | 23 | 0.150 |
Why?
|
| Calcium Channel Blockers | 1 | 1997 | 203 | 0.140 |
Why?
|
| Methadone | 1 | 1996 | 36 | 0.140 |
Why?
|
| Pyrimidines | 1 | 2019 | 370 | 0.140 |
Why?
|
| Dronabinol | 3 | 1992 | 53 | 0.140 |
Why?
|
| Self Administration | 3 | 2008 | 73 | 0.140 |
Why?
|
| Central Nervous System Stimulants | 1 | 2018 | 216 | 0.140 |
Why?
|
| Flumazenil | 1 | 1995 | 8 | 0.140 |
Why?
|
| Accidents, Traffic | 1 | 1996 | 94 | 0.130 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 1995 | 48 | 0.130 |
Why?
|
| Basal Cell Nevus Syndrome | 1 | 2015 | 4 | 0.130 |
Why?
|
| Practice Guidelines as Topic | 2 | 2012 | 1036 | 0.130 |
Why?
|
| Miosis | 3 | 2004 | 10 | 0.130 |
Why?
|
| Treatment Outcome | 4 | 2019 | 7993 | 0.130 |
Why?
|
| Anilides | 1 | 2015 | 47 | 0.130 |
Why?
|
| Breath Tests | 4 | 2001 | 55 | 0.130 |
Why?
|
| Respiratory Mechanics | 2 | 2008 | 102 | 0.120 |
Why?
|
| Quaternary Ammonium Compounds | 1 | 2014 | 79 | 0.120 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 1996 | 243 | 0.120 |
Why?
|
| Nifedipine | 1 | 1993 | 28 | 0.120 |
Why?
|
| Stress, Physiological | 1 | 1995 | 227 | 0.120 |
Why?
|
| Population | 1 | 2013 | 35 | 0.120 |
Why?
|
| Radioimmunoassay | 1 | 1993 | 155 | 0.120 |
Why?
|
| Endpoint Determination | 1 | 2013 | 60 | 0.120 |
Why?
|
| Anesthesia, Intravenous | 1 | 1993 | 35 | 0.120 |
Why?
|
| Retrospective Studies | 4 | 2019 | 8489 | 0.120 |
Why?
|
| Hair | 1 | 1993 | 56 | 0.120 |
Why?
|
| Social Environment | 2 | 1992 | 188 | 0.110 |
Why?
|
| Ondansetron | 1 | 1993 | 21 | 0.110 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2013 | 172 | 0.110 |
Why?
|
| Tobacco Smoke Pollution | 1 | 1993 | 23 | 0.110 |
Why?
|
| Pyridines | 1 | 2015 | 310 | 0.110 |
Why?
|
| Substance Abuse, Intravenous | 1 | 1993 | 54 | 0.110 |
Why?
|
| Cycloparaffins | 1 | 1992 | 5 | 0.110 |
Why?
|
| Toxicity Tests, Acute | 1 | 2011 | 2 | 0.110 |
Why?
|
| Terminology as Topic | 1 | 2013 | 217 | 0.110 |
Why?
|
| Pregabalin | 1 | 2011 | 6 | 0.100 |
Why?
|
| Thinking | 1 | 2012 | 33 | 0.100 |
Why?
|
| Respiratory Rate | 1 | 2011 | 20 | 0.100 |
Why?
|
| Neurology | 1 | 2012 | 70 | 0.100 |
Why?
|
| Social Isolation | 1 | 1992 | 67 | 0.100 |
Why?
|
| Drug Discovery | 1 | 2012 | 103 | 0.100 |
Why?
|
| 3,4-Methylenedioxyamphetamine | 2 | 1990 | 5 | 0.100 |
Why?
|
| Socioeconomic Factors | 1 | 2013 | 567 | 0.100 |
Why?
|
| Drug Administration Schedule | 2 | 2019 | 916 | 0.100 |
Why?
|
| Plants, Toxic | 2 | 1987 | 26 | 0.090 |
Why?
|
| Amphetamines | 1 | 1990 | 18 | 0.090 |
Why?
|
| Leukemia, Myeloid | 1 | 2011 | 249 | 0.090 |
Why?
|
| Psychopharmacology | 1 | 2009 | 26 | 0.090 |
Why?
|
| Procaine | 1 | 1989 | 11 | 0.090 |
Why?
|
| Pentobarbital | 1 | 1989 | 20 | 0.090 |
Why?
|
| Social Values | 1 | 2009 | 44 | 0.090 |
Why?
|
| Cannabis | 1 | 1990 | 34 | 0.090 |
Why?
|
| Lidocaine | 1 | 1989 | 63 | 0.090 |
Why?
|
| Psychological Tests | 1 | 2009 | 91 | 0.090 |
Why?
|
| Conditioning, Operant | 4 | 2008 | 73 | 0.090 |
Why?
|
| Cotinine | 3 | 1997 | 12 | 0.090 |
Why?
|
| Methamphetamine | 1 | 1990 | 82 | 0.080 |
Why?
|
| Cocaine | 1 | 1989 | 76 | 0.080 |
Why?
|
| Norepinephrine | 3 | 2005 | 167 | 0.080 |
Why?
|
| Drug Evaluation | 1 | 2008 | 141 | 0.080 |
Why?
|
| Placebo Effect | 1 | 2008 | 31 | 0.080 |
Why?
|
| Drug Design | 1 | 2008 | 124 | 0.080 |
Why?
|
| Reward | 1 | 2009 | 181 | 0.080 |
Why?
|
| Health Surveys | 1 | 2008 | 239 | 0.070 |
Why?
|
| Clinical Trials as Topic | 1 | 2012 | 1169 | 0.070 |
Why?
|
| Pharmaceutical Preparations | 1 | 2008 | 92 | 0.070 |
Why?
|
| Smoke | 1 | 1986 | 27 | 0.070 |
Why?
|
| Neoplasms | 2 | 2019 | 2898 | 0.070 |
Why?
|
| Case-Control Studies | 1 | 2011 | 1805 | 0.070 |
Why?
|
| Middle Aged | 8 | 2019 | 25028 | 0.070 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2006 | 24 | 0.070 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2008 | 199 | 0.070 |
Why?
|
| Ambulatory Surgical Procedures | 3 | 1995 | 74 | 0.070 |
Why?
|
| Drug Therapy, Combination | 2 | 2019 | 894 | 0.070 |
Why?
|
| Water | 2 | 1997 | 277 | 0.060 |
Why?
|
| Self Concept | 1 | 2005 | 133 | 0.060 |
Why?
|
| Heroin Dependence | 2 | 2011 | 14 | 0.060 |
Why?
|
| Forearm | 1 | 2004 | 32 | 0.060 |
Why?
|
| Drug Synergism | 2 | 1998 | 303 | 0.060 |
Why?
|
| Serotonin | 1 | 2005 | 218 | 0.060 |
Why?
|
| Prevalence | 1 | 2008 | 1239 | 0.060 |
Why?
|
| Oxygen | 3 | 1999 | 726 | 0.060 |
Why?
|
| Lysergic Acid Diethylamide | 1 | 2004 | 22 | 0.060 |
Why?
|
| Reinforcement Schedule | 3 | 2008 | 18 | 0.060 |
Why?
|
| Plant Extracts | 1 | 2004 | 244 | 0.050 |
Why?
|
| Adolescent | 5 | 1993 | 8981 | 0.050 |
Why?
|
| Volunteers | 1 | 2001 | 19 | 0.050 |
Why?
|
| Random Allocation | 2 | 1993 | 332 | 0.050 |
Why?
|
| Amitriptyline | 1 | 2001 | 11 | 0.050 |
Why?
|
| Statistics as Topic | 1 | 2002 | 238 | 0.050 |
Why?
|
| Gait | 1 | 2001 | 80 | 0.050 |
Why?
|
| Antidepressive Agents | 1 | 2001 | 106 | 0.050 |
Why?
|
| Sleep | 2 | 1996 | 444 | 0.050 |
Why?
|
| Consumer Behavior | 1 | 1999 | 29 | 0.040 |
Why?
|
| Sensation | 1 | 1999 | 45 | 0.040 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2019 | 56 | 0.040 |
Why?
|
| Indazoles | 1 | 2019 | 68 | 0.040 |
Why?
|
| Aged | 4 | 2019 | 18415 | 0.040 |
Why?
|
| Risk Assessment | 2 | 2019 | 2261 | 0.040 |
Why?
|
| Incidence | 1 | 2003 | 1577 | 0.040 |
Why?
|
| Drug Utilization | 1 | 1999 | 65 | 0.040 |
Why?
|
| Attitude | 1 | 1999 | 127 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 1 | 2019 | 270 | 0.040 |
Why?
|
| Patient Satisfaction | 1 | 2001 | 455 | 0.040 |
Why?
|
| Nimodipine | 1 | 1997 | 11 | 0.040 |
Why?
|
| Diltiazem | 1 | 1997 | 17 | 0.040 |
Why?
|
| Cross-Sectional Studies | 1 | 2003 | 1621 | 0.040 |
Why?
|
| Mental Competency | 1 | 1997 | 49 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 1 | 2019 | 552 | 0.040 |
Why?
|
| Infusion Pumps | 1 | 1996 | 25 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2019 | 860 | 0.040 |
Why?
|
| Behavior, Animal | 1 | 1999 | 373 | 0.040 |
Why?
|
| Recurrence | 1 | 1999 | 1139 | 0.040 |
Why?
|
| Patient Safety | 1 | 2019 | 212 | 0.040 |
Why?
|
| Motor Activity | 1 | 1999 | 327 | 0.040 |
Why?
|
| Columbidae | 4 | 1990 | 4 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2019 | 1204 | 0.040 |
Why?
|
| Work Schedule Tolerance | 1 | 1996 | 36 | 0.030 |
Why?
|
| Long-Term Care | 1 | 1996 | 61 | 0.030 |
Why?
|
| United States | 2 | 2012 | 6672 | 0.030 |
Why?
|
| Administration, Intranasal | 1 | 1996 | 136 | 0.030 |
Why?
|
| Coffee | 1 | 1995 | 10 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 1996 | 153 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2019 | 1538 | 0.030 |
Why?
|
| Informed Consent | 1 | 1997 | 266 | 0.030 |
Why?
|
| Sleep Deprivation | 1 | 1996 | 137 | 0.030 |
Why?
|
| Pressure | 1 | 1995 | 165 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2002 | 3640 | 0.030 |
Why?
|
| Nervous System Diseases | 1 | 1995 | 151 | 0.030 |
Why?
|
| Personality Inventory | 1 | 1994 | 108 | 0.030 |
Why?
|
| Chronic Disease | 1 | 1998 | 971 | 0.030 |
Why?
|
| Temperature | 1 | 1995 | 396 | 0.030 |
Why?
|
| Age Factors | 1 | 2019 | 1851 | 0.030 |
Why?
|
| Reflex, Pupillary | 1 | 1994 | 7 | 0.030 |
Why?
|
| Sufentanil | 1 | 1993 | 3 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2019 | 1939 | 0.030 |
Why?
|
| Smell | 1 | 1994 | 109 | 0.030 |
Why?
|
| Generalization, Stimulus | 2 | 1990 | 3 | 0.030 |
Why?
|
| Models, Biological | 1 | 1999 | 1749 | 0.030 |
Why?
|
| Pulse | 1 | 1992 | 18 | 0.030 |
Why?
|
| Internationality | 1 | 2012 | 69 | 0.030 |
Why?
|
| Tetrahydronaphthalenes | 1 | 1992 | 15 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2019 | 2767 | 0.030 |
Why?
|
| N-Methyl-3,4-methylenedioxyamphetamine | 2 | 1990 | 68 | 0.030 |
Why?
|
| Animals | 6 | 1999 | 26582 | 0.030 |
Why?
|
| Hunger | 1 | 1992 | 23 | 0.030 |
Why?
|
| Verbal Behavior | 1 | 1992 | 32 | 0.030 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 1992 | 76 | 0.030 |
Why?
|
| Memory, Short-Term | 3 | 2005 | 220 | 0.030 |
Why?
|
| Personality Assessment | 1 | 1992 | 98 | 0.030 |
Why?
|
| Energy Intake | 1 | 1992 | 98 | 0.030 |
Why?
|
| Daunorubicin | 1 | 2011 | 78 | 0.030 |
Why?
|
| Ketone Bodies | 1 | 1991 | 17 | 0.030 |
Why?
|
| Dopamine | 2 | 1983 | 275 | 0.020 |
Why?
|
| Hormones | 1 | 2011 | 141 | 0.020 |
Why?
|
| Cytarabine | 1 | 2011 | 218 | 0.020 |
Why?
|
| Carbon Dioxide | 1 | 1992 | 188 | 0.020 |
Why?
|
| Fenfluramine | 1 | 1990 | 20 | 0.020 |
Why?
|
| Smoking Cessation | 1 | 1993 | 230 | 0.020 |
Why?
|
| Drinking Behavior | 1 | 1990 | 13 | 0.020 |
Why?
|
| Glycosuria | 1 | 1989 | 5 | 0.020 |
Why?
|
| Sodium Chloride | 1 | 1990 | 88 | 0.020 |
Why?
|
| Rats, Inbred Strains | 1 | 1990 | 312 | 0.020 |
Why?
|
| Amphetamine | 1 | 1990 | 101 | 0.020 |
Why?
|
| Cocaine-Related Disorders | 1 | 2008 | 34 | 0.020 |
Why?
|
| Filtration | 1 | 1986 | 25 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2010 | 814 | 0.020 |
Why?
|
| Volatilization | 1 | 2005 | 5 | 0.020 |
Why?
|
| Time Perception | 1 | 2005 | 24 | 0.020 |
Why?
|
| Verbal Learning | 1 | 2005 | 30 | 0.020 |
Why?
|
| Blood Glucose | 1 | 1989 | 873 | 0.020 |
Why?
|
| Problem Solving | 1 | 2005 | 54 | 0.020 |
Why?
|
| Discrimination Learning | 1 | 2005 | 63 | 0.020 |
Why?
|
| Conscious Sedation | 1 | 2005 | 64 | 0.020 |
Why?
|
| Rats | 1 | 1990 | 3990 | 0.010 |
Why?
|
| Stereotyped Behavior | 1 | 1983 | 11 | 0.010 |
Why?
|
| Telencephalon | 1 | 1982 | 31 | 0.010 |
Why?
|
| Serotonin Uptake Inhibitors | 1 | 2001 | 7 | 0.010 |
Why?
|
| Desipramine | 1 | 2001 | 9 | 0.010 |
Why?
|
| Brain | 1 | 2011 | 2216 | 0.010 |
Why?
|
| Paroxetine | 1 | 2001 | 26 | 0.010 |
Why?
|
| Lung | 1 | 1987 | 1170 | 0.010 |
Why?
|
| Oxygen Consumption | 1 | 2001 | 239 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2011 | 2360 | 0.010 |
Why?
|
| Stress, Psychological | 1 | 1983 | 313 | 0.010 |
Why?
|
| Droperidol | 1 | 1995 | 3 | 0.010 |
Why?
|
| Ketamine | 1 | 1995 | 24 | 0.010 |
Why?
|
| Reference Standards | 1 | 1995 | 159 | 0.010 |
Why?
|
| Postoperative Period | 1 | 1991 | 303 | 0.010 |
Why?
|
| Learning | 1 | 1993 | 280 | 0.010 |
Why?
|
| Apomorphine | 1 | 1983 | 10 | 0.000 |
Why?
|
| Haloperidol | 1 | 1983 | 30 | 0.000 |
Why?
|
| Pons | 1 | 1982 | 24 | 0.000 |
Why?
|
| Substantia Nigra | 1 | 1982 | 27 | 0.000 |
Why?
|
| Basal Ganglia | 1 | 1982 | 42 | 0.000 |
Why?
|
| Brain Chemistry | 1 | 1983 | 121 | 0.000 |
Why?
|
| Olfactory Bulb | 1 | 1982 | 40 | 0.000 |
Why?
|
| Corpus Striatum | 1 | 1982 | 86 | 0.000 |
Why?
|
| Eating | 1 | 1983 | 166 | 0.000 |
Why?
|
| Neural Pathways | 1 | 1982 | 308 | 0.000 |
Why?
|